Avicanna Partners with Vectura Fertin Pharma to Advance Medical Cannabis Research in Canada
January 16, 2025
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Avicanna (TSX: AVCN) (OTCQX: AVCNF) has announced a scientific and medical affairs collaboration with Vectura Fertin Pharma. The partnership involves establishing a joint Scientific and Medical Affairs Committee focused on enhancing understanding of medical cannabis access and applications in Canada.
The collaboration will focus on working with Canadian healthcare professionals to facilitate research studies and provide evidence-based educational resources. Key objectives include engaging with the medical community, patients, advocacy groups, and insurers to understand medical cannabis access challenges. The initiative will utilize Avicanna’s medical cannabis platform, Mymedi.ca, to improve access and patient support.
Avicanna (TSX: AVCN) (OTCQX: AVCNF) ha annunciato una collaborazione nei settori scientifico e medico con Vectura Fertin Pharma. La partnership prevede l’istituzione di un Comitato congiunto di Affari Scientifici e Medici, focalizzato sul miglioramento della comprensione dell’accesso e delle applicazioni della cannabis medica in Canada.
La collaborazione si concentrerà sul lavoro con i professionisti della salute canadese per facilitare studi di ricerca e fornire risorse educative basate su evidenze. Gli obiettivi principali includono il coinvolgimento della comunità medica, dei pazienti, dei gruppi di sostegno e degli assicuratori per comprendere le sfide relative all’accesso alla cannabis medica. L’iniziativa utilizzerà la piattaforma di cannabis medica di Avicanna, Mymedi.ca, per migliorare l’accesso e il supporto ai pazienti.
Avicanna (TSX: AVCN) (OTCQX: AVCNF) ha anunciado una colaboración en asuntos científicos y médicos con Vectura Fertin Pharma. La asociación implica el establecimiento de un Comité Conjunto de Asuntos Científicos y Médicos centrado en mejorar la comprensión del acceso y las aplicaciones de la cannabis médica en Canadá.
La colaboración se centrará en trabajar con profesionales de la salud canadienses para facilitar estudios de investigación y proporcionar recursos educativos basados en evidencia. Los objetivos clave incluyen involucrar a la comunidad médica, pacientes, grupos de defensa y aseguradoras para comprender los desafíos del acceso a la cannabis médica. La iniciativa utilizará la plataforma de cannabis médica de Avicanna, Mymedi.ca, para mejorar el acceso y el apoyo a los pacientes.
Avicanna (TSX: AVCN) (OTCQX: AVCNF)는 Vectura Fertin Pharma와 과학 및 의료 분야의 협력 관계를 발표했습니다. 이 파트너십은 캐나다에서의 의료용 대마초 접근과 응용에 대한 이해를 높이기 위해 공동 과학 및 의료 위원회를 설립하는 것을 포함합니다.
협력은 캐나다의 의료 전문가와 협력하여 연구를 촉진하고 증거 기반 교육 자료를 제공하는 데 초점을 맞출 것입니다. 주요 목표는 의료 커뮤니티, 환자, 지지 그룹 및 보험사와 협력하여 의료용 대마초 접근의 도전 과제를 이해하는 것입니다. 이 이니셔티브는 Avicanna의 의료용 대마초 플랫폼인 Mymedi.ca를 활용하여 접근성과 환자 지원을 향상시킬 것입니다.
Avicanna (TSX: AVCN) (OTCQX: AVCNF) a annoncé une collaboration dans les affaires scientifiques et médicales avec Vectura Fertin Pharma. Ce partenariat implique la création d’un Comité conjoint des affaires scientifiques et médicales axé sur l’amélioration de la compréhension de l’accès et des applications du cannabis médical au Canada.
La collaboration se concentrera sur le travail avec des professionnels de la santé canadiens pour faciliter des études de recherche et fournir des ressources éducatives basées sur des preuves. Les principaux objectifs incluent l’engagement avec la communauté médicale, les patients, les groupes de défense et les assureurs pour comprendre les défis d’accès au cannabis médical. L’initiative utilisera la plateforme de cannabis médical d’Avicanna, Mymedi.ca, pour améliorer l’accès et le soutien aux patients.
Avicanna (TSX: AVCN) (OTCQX: AVCNF) hat eine wissenschaftliche und medizinische Zusammenarbeit mit Vectura Fertin Pharma angekündigt. Die Partnerschaft umfasst die Einrichtung eines gemeinsamen Ausschusses für wissenschaftliche und medizinische Angelegenheiten, der sich darauf konzentriert, das Verständnis des Zugangs und der Anwendungen von medizinischem Cannabis in Kanada zu verbessern.
Die Zusammenarbeit wird sich darauf konzentrieren, mit kanadischen Gesundheitsfachleuten zusammenzuarbeiten, um Forschungsstudien zu erleichtern und evidenzbasierte Bildungsressourcen bereitzustellen. Zu den Hauptzielen gehört es, mit der medizinischen Gemeinschaft, Patienten, Interessenverbänden und Versicherern in Kontakt zu treten, um die Herausforderungen beim Zugang zu medizinischem Cannabis zu verstehen. Die Initiative wird die medizinische Cannabis-Plattform von Avicanna, Mymedi.ca, nutzen, um den Zugang und die Patientenunterstützung zu verbessern.
Positive
- Strategic partnership with established pharmaceutical company Vectura Fertin Pharma
- Potential to improve medical cannabis access and market penetration in Canada
- Enhancement of research and evidence-based educational resources
Negative
01/16/2025 – 07:30 AM
Collaboration aims to facilitate research and medical affairs initiatives related to medical cannabis in Canada
TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that Avicanna has entered into a scientific and medical affairs collaboration agreement with Vectura Fertin Pharma.
Avicanna and Vectura Fertin Pharma are collaborating to establish a joint Scientific and Medical Affairs Committee focused on improving the understanding of medical cannabis access and applications in Canada. This committee will work closely with Canadian healthcare professionals to facilitate research studies and deliver evidence-based educational resources.
The collaboration will prioritize engagement with the Canadian medical community, patients, patient advocacy groups, and insurers to gain insights into the challenges associated with accessing medical cannabis. Additionally, the collaboration will leverage Avicanna’s medical cannabis platform, including Mymedi.ca with the aim of improving access and patient support.
About Vectura Fertin Pharma:
At Vectura Fertin Pharma, we are developing and commercializing a proprietary pipeline of differentiated products and brands in wellness and healthcare that address unmet patient and consumer needs. We have unique R&D capabilities which we are applying across four key areas: Cannabinoids, Inhaled Therapeutics, Nicotine Replacement Therapy and Consumer Health. Underpinned by scientific rigor, and patient and consumer insights, we are passionate about finding new and better ways to help people take care of their health and wellbeing. Vectura Fertin Pharma was formed in March 2022 following the acquisition of Fertin Pharma, Vectura Group PLC and OtiTopic by Philip Morris International.
About Avicanna:
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
- Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
- Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
- Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.
- Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
What is the purpose of Avicanna’s (AVCNF) collaboration with Vectura Fertin Pharma?
The collaboration aims to improve understanding of medical cannabis access and applications in Canada through research studies and evidence-based educational resources.
How will AVCNF’s partnership with Vectura Fertin Pharma benefit healthcare professionals?
The partnership will work with healthcare professionals to facilitate research studies and provide evidence-based educational resources about medical cannabis.
What role will Avicanna’s Mymedi.ca platform play in the Vectura Fertin Pharma collaboration?
The Mymedi.ca platform will be leveraged to improve medical cannabis access and patient support as part of the collaboration.
Which stakeholders will be engaged in AVCNF’s medical cannabis initiative with Vectura Fertin?
The initiative will engage with the Canadian medical community, patients, patient advocacy groups, and insurers to understand medical cannabis access challenges.
Search
RECENT PRESS RELEASES
